Mac‐2 Binding Protein Glycan Isomer as non‐invasive tool to assess liver fibrosis in children with chronic liver disease

2021 ◽  
Author(s):  
Ola G Behairy ◽  
Soha A El‐Gendy ◽  
Dalia Y Ibrahim ◽  
Amira I Mansour ◽  
Ola S El‐Shimi
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Binding Protein ◽  
Chronic Liver ◽  
Non Invasive

scholarly journals Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study

2012 ◽  
Vol 11 (3) ◽  
pp. 364-368 ◽  
Author(s):  
Judith Flores-Calderón ◽  
Segundo Morán-Villota ◽  
Guillermo Ramón-García ◽  
Berenice González-Romano ◽  
María del Carmen Bojórquez-Ramos ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Multicenter Study ◽  
Chronic Liver ◽  
Non Invasive ◽  
Mexican Children

scholarly journals Rule of Mac-2 Binding Protein Glycan Isomer in Assessment of Liver Fibrosis in Children with Chronic Liver Disease

2020 ◽  
Vol 5 (3) ◽  
pp. 1-9
Author(s):  
S.A. El-Gendy ◽  
O.G. Behairy ◽  
A.I. Mansour ◽  
O.S. El-Shimi ◽  
D.Y. Ibrahim
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Binding Protein ◽  
Chronic Liver

scholarly journals A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease

2019 ◽  
Vol 57 (1) ◽  
pp. 36-43
Author(s):  
Preya Janubhai Patel ◽  
Declan Connoley ◽  
Freya Rhodes ◽  
Ankur Srivastava ◽  
William Rosenberg
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Chronic Liver Disease ◽  
Clinical Utility ◽  
Chronic Liver ◽  
Biliary Cirrhosis ◽  
Alcoholic Fatty Liver ◽  
Functional Changes ◽  
Non Invasive

The rising incidence of chronic liver disease continues to be an increasing health burden. The morbidity and mortality associated with chronic liver disease typically occur in patients with advanced fibrosis. Hence, early identification of those at-risk is of vital importance to ensure appropriate ongoing management. Currently, tools for appropriate risk stratification remain limited. Increasing awareness of the limitations of liver biopsy has driven research into alternative non-invasive methods of fibrosis assessment including serological markers assessing functional changes. One such biomarker, the Enhanced Liver Fibrosis test, was initially validated in a cohort of 1021 patients with mixed aetiology chronic liver disease and shown to perform well. Since this pathfinder study, it has been independently validated in cohorts of hepatitis C, non-alcoholic fatty liver disease, alcoholic liver disease, primary biliary cirrhosis and primary sclerosing cholangitis. In addition to performing well as a diagnostic tool, the Enhanced Liver Fibrosis test has been shown to outperform liver biopsy in prognostic studies and is the only non-invasive marker to do so. However, questions remain regarding the use of this test, particularly regarding the possible effect age and alcohol may have on test scores. This review examines the current literature published in relation to the Enhanced Liver Fibrosis test and its clinical utility and highlights areas requiring further study.

scholarly journals Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease

2016 ◽  
Vol 52 (1) ◽  
pp. 107-115 ◽  
Author(s):  
Swastik Agrawal ◽  
Caroline L. Hoad ◽  
Susan T. Francis ◽  
Indra N. Guha ◽  
Philip Kaye ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Non Invasive

scholarly journals Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review

2019 ◽  
Vol 57 (5) ◽  
pp. 577-610 ◽  
Author(s):  
Seyyed Mortaza Haghgoo ◽  
Heidar Sharafi ◽  
Seyed Moayed Alavian
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Growth Factor ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Serum Levels ◽  
Chronic Liver ◽  
Major Health Problem ◽  
Non Invasive ◽  
Tgf Β1

AbstractChronic liver disease (CLD) is a major health problem worldwide. Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis C (CHC), chronic hepatitis B (CHB), and alcoholic liver disease (ALD) are the most common etiologies of CLD. Liver biopsy is the gold standard for assessment of liver fibrosis, however, it is an invasive method. This review attempts to evaluate the usefulness of serum adiponectin, serum leptin, serum ferritin, serum transforming growth factor-β1 (TGF-β1), and serum platelet derived growth factor-BB (PDGF-BB) as non-invasive markers in the diagnosis of liver fibrosis/cirrhosis. A systematic search in MEDLINE, Web of Science, Scopus, and local databases was performed to identify articles published in English or Persian as of November 2017. Studies conducted among CLD patients, with biopsy proven fibrosis/cirrhosis, and providing sufficient details of patients’ clinicopathological characteristics were included. In the 95 studies included, there were a total of 15,548 CLD patients. More than 83% of studies were carried out in Asia and Europe. The relationship between liver fibrosis/cirrhosis and serum levels of ferritin, adiponectin, leptin, TGF-β1, and PDGF-BB was assessed in 42, 33, 27, nine, and three studies, respectively. Serum levels of the markers, particularly ferritin, could successfully predict liver fibrosis/cirrhosis, however, these data might not be clinically replicated and further studies are needed.

Sign in / Sign up

Export Citation Format

Share Document